Rising Shares at Clarity Pharmaceuticals as it Launches Second Phase III Trial and Promotes Michelle Parker to CEO
Biotech firm Clarity Pharmaceuticals is preparing to initiate a second Phase III clinical trial for its prostate cancer diagnostic product, 64Cu-SAR-bisPSMA, after receiving positive feedback from the US Food and Drug Administration (FDA). This announcement has boosted the company’s shares. The new trial, named AMPLIFY, will involve approximately 220 participants...